These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Drug Safety Strategies to De-Risk Compounds--an IBC conference. 4-6 August 2009, Boston, MA, USA. Mattes W IDrugs; 2009 Oct; 12(10):623-6. PubMed ID: 19790010 [TBL] [Abstract][Full Text] [Related]
14. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity. Zhang A; Sun H; Wang P; Han Y; Wang X Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077 [TBL] [Abstract][Full Text] [Related]
15. SMi's Conducting Clinical Trials in Europe. Jago C IDrugs; 2009 Dec; 12(12):754-9. PubMed ID: 19943216 [TBL] [Abstract][Full Text] [Related]
16. Safety biomarkers in preclinical development: translational potential. Sasseville VG; Mansfield KG; Brees DJ Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials in cancer - SMi's Seventh Annual Conference. Fakorede A IDrugs; 2008 Sep; 11(9):627-9. PubMed ID: 18763208 [No Abstract] [Full Text] [Related]
18. Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury. Kane-Gill SL; Smithburger PL; Kashani K; Kellum JA; Frazee E Drug Saf; 2017 Nov; 40(11):1049-1074. PubMed ID: 28674842 [TBL] [Abstract][Full Text] [Related]
19. Qualification of translational safety biomarkers. Sauer JM; Porter AC Exp Biol Med (Maywood); 2021 Nov; 246(22):2391-2398. PubMed ID: 33757340 [TBL] [Abstract][Full Text] [Related]
20. Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. Dadarkar SS; Fonseca LC; Mishra PB; Lobo AS; Doshi LS; Dagia NM; Rangasamy AK; Padigaru M J Appl Toxicol; 2011 Mar; 31(2):117-30. PubMed ID: 20623750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]